Floatz logo

tng462

Lung Cancer

Tango Therapeutics, Inc.Phase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

303 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
Carboplatin
SystImmune Inc.
Phase 4BB
Nivolumab
University of Chicago
Phase 4BB
PROPOFOL
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BB

View all 50 →

Same molecule, other indications

tng462 is also rated in:

MTAP-deleted Solid TumorsDormant
CC
Indicative ·
47 / 100
View asset →
RAS MutationDormant
CC
Indicative ·
45 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →